| 000 | nam a22 a 4500 | ||
|---|---|---|---|
| 999 |
_c24736 _d24736 |
||
| 001 | BD-DhNSU-24736 | ||
| 003 | BD-DhNSU | ||
| 005 | 20190403071228.0 | ||
| 008 | 190403s2010 nyua|||g |||| 001 0|eng d | ||
| 010 | _a | ||
| 020 | _a9781439803363 | ||
| 040 |
_aDLC _cDLC _dBD-DhNSU |
||
| 041 | _aeng | ||
| 050 | 0 | 0 |
_aRM301.25 _b.A28 2010 |
| 245 | 0 | 0 |
_aActive pharmaceutical ingredients : _bdevelopment, manufacturing, and regulation / _cedited by Stanley H. Nusim |
| 250 | _a2nd ed. | ||
| 260 |
_aNew York : _bInforma Healthcare, _cc2010. |
||
| 300 |
_axv, 433 p. : _bill. ; _c24 cm. |
||
| 490 | 1 | _aDrugs and the pharmaceutical sciences ; No 205 | |
| 650 | 0 | _aDrug development organization | |
| 650 | 4 | _aPharmaceutical technology | |
| 650 | 4 | _aDrugs | |
| 700 | 1 | _aNusim, Stanley H. | |
| 942 |
_2lcc _cBK |
||